22042-26042

Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma: a phase II trial 
(D. Weber)

 

22043-30041

Phase III pathological stage T3 a-b R 0-1 N0, pT2 R1 N0 Gleason score 5-10 prostatic carcinoma
(M.Bolla,H. Van Poppel)

 

22051-10052

SUPREMO: a phase III (Scottish Trials Office, UK)
(I. Kunkler, G. Van Tienhoven)

 

26053-22054

CATNON: anaplastic glioma without 1p19q loss (EORTC/NCI-C/RTOG/Cancer UK/HUB/NOA intergroup)
(M.Van den Bent, B. Baumert)

 

22061-26062

Randomized phase III newly diagnosed glioblastoma multiforme in elderly patients (A. Brandes, J. Menten)

 

40054-22062
 (PETACC-6)

Phase III in locally advanced rectal cancer
(E. van Cutsem, K. Haustermans)

 

22071-24071

Randomized phase III trial on postoperative chemoradiation in combination with an EGFR-antibody versus postoperative chemoradiation in head and neck squamous cell carcinoma (HNSCC) with high risk of locoregional recurrence.
(W. Budach, H.Langendijk)

 

26071-22072

Cilengitide in newly diagnosed GBM with methylated MGMT gene promoter – a multicentre open-label controlled phase III study: cilengitide plus standard treatment versus standard treatment alone (EORTC/Merck KgaA) R. Stupp, S. Erridge, M.Shilkrut)

 

08072-22074

CONVERT: concurrent once daily versus radiotherapy twice daily in limited disease SCLC a randomized phase III study
(C. Faivre Finn)

 

26082-22801

Temsirolimus (CCI-779) with concomitant radiation therapy, followed by temsirolimus maintenance therapy versus radiochemotherapy with concomitant and adjuvant temozolomide in subjects with newly diagnosed GBM without methylation of the MGMT gene promoter – a randomized multicentre open-label phase II study
(W.Wick, G. Pesce)

 

 >> next page...

 

 

EORTC